Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer
Hossein Fallahi
October 09, 2022
Cisplatin-based chemotherapy remains the primary treatment for unresectable and metastatic muscle-invasive bladder cancers (MIBCs). However, tumors frequently develop chemoresistance. Here, we established a primary and orthotopic MIBC mouse model with gene-edited organoids to recapitulate the full course of chemotherapy in patients. In a new paper, Wang et. al. found that partial squamous differentiation, called semi-squamatization, is associated with acquired chemoresistance in both mice and human MIBCs.